Medial-prefrontal Enhancement During Schizophrenia Systems Imaging

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT04807530
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • TMS — DEVICE
    The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)

Study Details

This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated repetitive transcranial magnetic stimulation (nrTMS) target in the medial/superior prefrontal cortex (mPFC); and 3) how modulation of mPFC activity impacts the larger self-agency network to mediate changes in self-agency judgments. Our overall hypothesis is that increased mPFC excitability by active high-frequency nrTMS in HC and SZ will induce behavioral improvements in self-agency and neural changes in the larger self-agency network that will generalize to improvements in overall cognition, symptoms and daily functioning, and will likely lead to the development of new effective neuromodulation therapies in patients with schizophrenia.

Key Dates

Start date
Nov 12, 2020
Status verified
Aug 2025
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
160 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Medial/Superior Prefrontal TMS
    10 Hz High frequency TMS applied to the mPFC
  • Placebo Comparator: Posterior Parietal TMS
    10 Hz high frequency TMS applied to the posterior parietal cortex

Primary Outcome Measure

Self-Agency Behavioral Change during Reality Monitoring after TMS vs Baseline (metrics of accuracy) [ Time Frame: From baseline, to immediately after TMS, up to 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UCSFSan FranciscoCalifornia94143
Miriam Mathew, PhD
[email protected]

Find similar trials in San Francisco, CA

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
UCSF· San Francisco, CA

Related Studies